PROKIDNEY CORP.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PROKIDNEY CORP. | ||
| Date: March 17, 2025 | By: | /s/ Bruce Culleton |
|---|---|---|
| Bruce Culleton | ||
| Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Bruce Culleton | Chief Executive Officer and Director | March 17, 2025 |
| Bruce Culleton | (Principal Executive Officer) | |
| /s/ James Coulston | Chief Financial Officer | March 17, 2025 |
| James Coulston | (Principal Financial and Accounting Officer) | |
| /s/ Pablo Legorreta | Chairman | March 17, 2025 |
| Pablo Legorreta | ||
| /s/ William F. Doyle | Director | March 17, 2025 |
| William F. Doyle | ||
| /s/ Jennifer Fox | Director | March 17, 2025 |
| Jennifer Fox | ||
| /s/ José Ignacio Jimenez Santos | Director | March 17, 2025 |
| José Ignacio Jimenez Santos | ||
| /s/ Alan M. Lotvin, M.D. | Director | March 17, 2025 |
| Alan M. Lotvin, M.D. | ||
| /s/ Brian J.G. Pereira, M.D. | Director | March 17, 2025 |
| Brian J.G. Pereira, M.D. | ||
| /s/ Uma Sinha, Ph.D. | Director | March 17, 2025 |
| Uma Sinha, Ph.D. | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID:42) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-3 |
| Consolidated Statements of Operations for the years ended December 31, 2024, 2023, and 2022 | F-4 |
| Consolidated Statements of Comprehensive Loss for the years ended December 31, 2024, 2023, and 2022 | F-5 |
| Consolidated Statements of Changes in Redeemable Noncontrolling Interest and Shareholders’ Deficit / Members’ Equity for the years ended December 31, 2024, 2023, and 2022 | F-6 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023, and 2022 | F-11 |
| Notes to Consolidated Financial Statements | F-14 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.